INT277828

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.22
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 1.27
Pain Relevance 0.57

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (ICAM1, ITGAL) plasma membrane (ICAM1, ITGAL) signal transduction (ITGAL)
extracellular space (ICAM1)
Anatomy Link Frequency
endothelial cells 3
T cells 3
ICAM1 (Homo sapiens)
ITGAL (Homo sapiens)
Pain Link Frequency Relevance Heat
psoriasis 174 97.24 Very High Very High Very High
Inflammation 24 73.68 Quite High
abatacept 4 68.72 Quite High
cytokine 63 5.00 Very Low Very Low Very Low
Infliximab 60 5.00 Very Low Very Low Very Low
Etanercept 49 5.00 Very Low Very Low Very Low
Adalimumab 27 5.00 Very Low Very Low Very Low
Arthritis 16 5.00 Very Low Very Low Very Low
rheumatoid arthritis 11 5.00 Very Low Very Low Very Low
chemokine 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adhesions 14 100.00 Very High Very High Very High
Leukocytosis 2 98.90 Very High Very High Very High
Psoriasis 200 97.24 Very High Very High Very High
INFLAMMATION 22 73.68 Quite High
Disease 45 51.00 Quite High
Opportunistic Infections 8 26.96 Quite Low
Hepatotoxicity 3 21.68 Low Low
Malignant Neoplastic Disease 7 21.16 Low Low
Nephrotoxicity 1 20.24 Low Low
Toxicity 10 9.92 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This drug binds to CD11a on T cells blocking the interaction between LFA-1 and intercellular adhesion molecule 1 (ICAM-1), its partner molecule for adhesion.
Negative_regulation (blocking) of ICAM-1 Binding (interaction) of LFA-1 in T cells associated with adhesions
1) Confidence 0.22 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721342 Disease Relevance 0.32 Pain Relevance 0.03
In a longterm clinical study, 50% of 228 patients with chronic plaque psoriasis achieved PASI 75 after 15 months of continuous efalizumab treatment, suggesting sustained efficacy with efalizumab.[24] Efalizumab was approved for treatment of psoriasis by FDA in 2003.[25] Administration of efalizumab induces a peripheral leukocytosis (predominantly of CD8+ memory cells), which is due to blockade of the LFA-1/ICAM-1 interaction between T cells and endothelial cells.
Negative_regulation (blockade) of ICAM-1 Binding (interaction) of LFA-1 in endothelial cells associated with psoriasis and leukocytosis
2) Confidence 0.02 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792605 Disease Relevance 0.47 Pain Relevance 0.27
In a longterm clinical study, 50% of 228 patients with chronic plaque psoriasis achieved PASI 75 after 15 months of continuous efalizumab treatment, suggesting sustained efficacy with efalizumab.[24] Efalizumab was approved for treatment of psoriasis by FDA in 2003.[25] Administration of efalizumab induces a peripheral leukocytosis (predominantly of CD8+ memory cells), which is due to blockade of the LFA-1/ICAM-1 interaction between T cells and endothelial cells.
Negative_regulation (blockade) of ICAM-1 in T cells Binding (interaction) of LFA-1 in endothelial cells associated with psoriasis and leukocytosis
3) Confidence 0.01 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792605 Disease Relevance 0.47 Pain Relevance 0.27

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox